Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 4Completed 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Breast 2Lymphoid 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1ER+ and AR+ Breast Cancer 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × ostarine × Breast × Clear all
NCT02971761 2024-02-20

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

City of Hope Medical Center

Phase 2 Completed
18 enrolled 17 charts
Breast

Triple Negative Breast Neoplasms

NCT02463032 2020-12-09

Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer

GTx

Phase 2 Completed
136 enrolled 14 charts
Breast

ER+ and AR+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡